Perinatal Mental Health Care Pathway

�This regional care pathway provides�guidance for all Health and Social Care (HSC) professionals who come into contact with pregnant women. In addition, each Trust has developed a local adaptation of this pathway for their population.�

Cervical screening: Frequently asked questions (FAQs)

Testing for high-risk human papillomavirus (HR-HPV) as triage and test of cure was introduced into the Northern Ireland Cervical Screening Programme on Monday 28 January 2013. This policy change will significantly alter the screening pathway for women with a mild dyskaryosis or borderline smear result. The link between HR-HPV infection and the development of cervical cancer has now been clearly established, with almost 100% of cervical cancers containing HPV DNA. Women with no evidence of HR-HPV infection are extremely unlikely to develop cervical cancer in the short to medium term. HPV triage is the process whereby HR-HPV testing is used to manage women with low grade cervical abnormalities. Only 15-20% of women with a borderline or mild smear result have a significant abnormality that needs treatment. HR-HPV testing is effective in identifying which women may need treatment and allows colposcopy resources to be allocated more effectively. The test of cure process is being introduced because it is now known that women with a normal or low grade smear test, and who are HR-HPV negative at six months after treatment, are at very low risk of residual disease. These women do not need to be recalled for another screening appointment for three years. The test of cure process means all post-treatment smears (at six months) that are reported as normal, borderline or mild dyskaryosis will be tested for HR-HPV. Those women who are HR-HPV positive will remain at colposcopy. HR-HPV negative women can be safely returned to recall in three years. It is estimated that the HR-HPV test of cure will allow approximately 80% of women who have been through treatment to avoid undergoing annual smear tests. These FAQs answer the most common and important queries in relation to HPV and the new screening process, and were distributed to all GPs in Northern Ireland. They can be downloaded as a PDF from this website.

C. difficile surveillance quarterly report: October - December 2012

This quarterly report provides epidemiological data on C. difficile in Northern Ireland, and includes key points, a comprehensive�overview of all C. diff infections, rates, trends, age-specific information�and statistical process control charts. The report also provides information on surveillance methods and data for each hospital and Health and Social Care Trust in Northern Ireland.

S.aureus bacteraemia surveillance quarterly report: October - December 2012

This quarterly report provides epidemiological data on�S. aureus�in Northern Ireland, including overall infection�figures as well as those specific to MRSA and MSSA. The report highlights key points, rates, trends and statistical process control charts. The report also provides information on surveillance methods and data for each hospital and Health and Social Care Trust in Northern Ireland

Pressure ulcer prevention

This leaflet provides information on pressure ulcers, how they develop and the steps patients and carers can take to prevent them.

Reducing the risk of human infection from pet rodents

The Health Protection Agency (HPA) has issued new guidance for owners of pet rodents following two recent UK cases of hantavirus which are described in a paper published in this week's Eurosurveillance.

Preventing food poisoning in hospital and at home

Information for patients and visitors on preventing food poisoning.

Cervical screening programme: HPV triage and test of cure protocol

Testing for high-risk human papillomavirus (HR-HPV) as triage and test of cure was introduced into the Northern Ireland Cervical Screening Programme on Monday 28 January 2013. This policy change will significantly alter the screening pathway for women with a mild dyskaryosis or borderline smear result. The link between HR-HPV infection and the development of cervical cancer has now been clearly established, with almost 100% of cervical cancers containing HPV DNA. Women with no evidence of HR-HPV infection are extremely unlikely to develop cervical cancer in the short to medium term. HPV triage is the process whereby HR-HPV testing is used to manage women with low grade cervical abnormalities. Only 15-20% of women with a borderline or mild smear result have a significant abnormality that needs treatment. HR-HPV testing is effective in identifying which women may need treatment and allows colposcopy resources to be allocated more effectively.The test of cure process is being introduced because it is now known that women with a normal or low grade smear test, and who are HR-HPV negative at six months after treatment, are at very low risk of residual disease. These women do not need to be recalled for another screening appointment for three years.The test of cure process means all post-treatment smears (at six months) that are reported as normal, borderline or mild dyskaryosis will be tested for HR-HPV. Those women who are HR-HPV positive will remain at colposcopy. HR-HPV negative women can be safely returned to recall in three years. It is estimated that the HR-HPV test of cure will allow approximately 80% of women who have been through treatment to avoid undergoing annual smear tests. This flowchart poster outlines the new triage and test of cure process. It was distributed to all GPs in Northern Ireland and is available to download as a PDF from this website.�

Stroke campaign - Leaflet, posters and wallet card

The F.A.S.T materials (poster/leaflet/wallet card) convey the signs and symptoms of stroke, and the call to action, that it's a medical emergency to call 999 immediately if you see any one of these signs. A fast response to the signs and symptoms of stroke can reduce the long term health consequences such as disability and death. Attached below are the�public information leaflets (male and female version), posters and wallet card available as part of the campaign.

Quit Kit Poster

The Quit Kit promotional materials were developed as part of the smoking cessation campaign which highlights the range of support available and reinforces the message that quitting is achievable with the right support and motivation. Support highlighted in this part of the campaign includes the smoking support services, GP/pharmacy support, helpline, web site www.want2stop.info and a quit kit. �The Quit Kit poster directs individuals to the smokers helpline 0808 812 8008 and www.want2stop.info to register for free Quit Kit

Quit Kit Flyer

The Quit Kit promotional materials were developed as part of the smoking cessation campaign which highlights the range of support available and reinforces the message that quitting is achievable with the right support and motivation. Support highlighted in this part of the campaign includes the smoking support services, GP/pharmacy support, helpline, web site www.want2stop.info and a quit kit. �The Quit Kit flyer allows individuals to register for free Quit Kit on completion of flyer.

Midwives and medicines

This leaflet was developed for midwives and describes midwives' role in administering and supplying medicines. It should be read in conjunction with the Nursing and Midwifery Council rules, standards and guidance. It is only available from the Local Supervising Authority Midwifery Officer at the PHA.

Whooping Cough (Pertussis) immunisation - Poster

This poster encourages uptake of the whooping cough vaccine for pregnant women. Cases of whooping cough are on the increase - by getting the vaccine while pregnant you can protect your baby.

Whooping Cough (Pertussis) immunisation for pregnant women - Factsheet

This factsheet provides information and encourages uptake of the whooping cough vaccine for pregnant women. Cases of whooping cough are on the increase - by getting the vaccine while pregnant you can protect your baby.

Protecting you and your baby: Blood tests at your first antenatal visit

This leaflet gives information on the blood tests that are normally offered and recommended at the first antenatal visit. These tests look for possible health problems that could affect the mother's health and the health of the baby. Only one sample of blood is needed to do all six tests. The tests are done by consent and this leaflet should help pregnant women make their decision.